3M Company vs Regeneron Pharmaceuticals Inc — how do they compare? 3M Company trades at $164.59 (market cap $86.39B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: 3M Company and Regeneron Pharmaceuticals Inc are close in size by market cap, and 3M Company pays the higher dividend (1.86%). Which is the better fit depends on your goals.
| MMM | REGN | |
|---|---|---|
Market Cap | $86.39B | $83.43B |
Sector | Industrials | Health |
52-Week High | $183.79 | $852.03 |
52-Week Low | $141.10 | $555.51 |
Enterprise Value | $95.61B | $78.14B |
Dividend Yield | 1.86% | 0.46% |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong recent earnings beats. The company shows solid profitability with an 11.9% net income margin and 82.77% ROE, though revenue has declined from 2022 peaks. Positive news highlights strength in transportation, electronics, and safety segments, while consumer demand remains soft.
The stock offers a balanced outlook: analyst consensus is a Buy with a $173 price target, but high debt and cost pressures pose risks. Earnings momentum from industrial growth supports upside, yet valuation multiples like a 29.75 P/E suggest limited margin for error. Investors should weigh robust fundamentals against macroeconomic and segment-specific headwinds.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →